Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Resource
  • Published:

Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza

An Author Correction to this article was published on 07 February 2019

This article has been updated

Abstract

Transcriptional profiles and host-response biomarkers are used increasingly to investigate the severity, subtype and pathogenesis of disease. We now describe whole-blood mRNA signatures and concentrations of local and systemic immunological mediators in 131 adults hospitalized with influenza, from whom extensive clinical and investigational data were obtained by MOSAIC investigators. Signatures reflective of interferon-related antiviral pathways were common up to day 4 of symptoms in patients who did not require mechanical ventilator support; in those who needed mechanical ventilation, an inflammatory, activated-neutrophil and cell-stress or death (‘bacterial’) pattern was seen, even early in disease. Identifiable bacterial co-infection was not necessary for this ‘bacterial’ signature but was able to enhance its development while attenuating the early ‘viral’ signature. Our findings emphasize the importance of timing and severity in the interpretation of host responses to acute viral infection and identify specific patterns of immune-system activation that might enable the development of novel diagnostic and therapeutic tools for severe influenza.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Transcriptional signature of patients with influenza compared with that of healthy control subjects.
Fig. 2: Severity of disease is associated with diminished expression of interferon-related modules and overexpression of inflammation modules.
Fig. 3: Severe disease is associated with lower expression of ‘viral response genes’ than their expression during early and less-severe influenza.
Fig. 4: Relationships among severity of illness, duration, bacterial infection, PCT and molecular scores.
Fig. 5: Concentration of selected mediators in various compartments according to severity of illness.
Fig. 6: Relationships among severity of illness, duration, bacterial infection, and selected mediators.

Similar content being viewed by others

Change history

  • 07 February 2019

    In the version of this article initially published, a source of funding was not included in the Acknowledgements section. That section should include the following: P.J.M.O. was supported by EU FP7 PREPARE project 602525. The error has been corrected in the HTML and PDF version of the article.

References

  1. Stöhr, K. Preventing and treating influenza. Br. Med. J. 326, 1223–1224 (2003).

    Article  Google Scholar 

  2. Hayward, A. C. et al. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. Lancet Respir. Med. 2, 445–454 (2014).

    Article  Google Scholar 

  3. Dawood, F. S. et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect. Dis. 12, 687–695 (2012).

    Article  Google Scholar 

  4. Bautista, E. et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N. Engl. J. Med. 362, 1708–1719 (2010).

    Article  Google Scholar 

  5. Hui, D. S., Lee, N. & Chan, P. K. Clinical management of pandemic 2009 influenza A(H1N1) infection. Chest 137, 916–925 (2010).

    Article  Google Scholar 

  6. Peiris, J. S., Cheung, C. Y., Leung, C. Y. & Nicholls, J. M. Innate immune responses to influenza A H5N1: friend or foe? Trends Immunol. 30, 574–584 (2009).

    Article  CAS  Google Scholar 

  7. Tisoncik, J. R. et al. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 76, 16–32 (2012).

    Article  CAS  Google Scholar 

  8. de Jong, M. D. et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12, 1203–1207 (2006).

    Article  Google Scholar 

  9. Ioannidis, I. et al. Plasticity and virus specificity of the airway epithelial cell immune response during respiratory virus infection. J. Virol. 86, 5422–5436 (2012).

    Article  CAS  Google Scholar 

  10. Ramilo, O. et al. Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood 109, 2066–2077 (2007).

    Article  CAS  Google Scholar 

  11. Zaas, A. K. et al. Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe 6, 207–217 (2009).

    Article  CAS  Google Scholar 

  12. Woods, C. W. et al. A host transcriptional signature for presymptomatic detection of infection in humans exposed to influenza H1N1 or H3N2. PLoS One 8, e52198 (2013).

    Article  CAS  Google Scholar 

  13. Nakaya, H. I. et al. Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. 12, 786–795 (2011).

    Article  CAS  Google Scholar 

  14. Li, S. et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 15, 195–204 (2014).

    Article  Google Scholar 

  15. Obermoser, G. et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity 38, 831–844 (2013).

    Article  CAS  Google Scholar 

  16. Blankley, S. et al. The application of transcriptional blood signatures to enhance our understanding of the host response to infection: the example of tuberculosis. Phil. Trans. R. Soc. Lond. B 369, 20130427 (2014).

    Article  Google Scholar 

  17. Pascual, V., Chaussabel, D. & Banchereau, J. A genomic approach to human autoimmune diseases. Annu. Rev. Immunol. 28, 535–571 (2010).

    Article  CAS  Google Scholar 

  18. Everitt, A. R. et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484, 519–523 (2012).

    Article  CAS  Google Scholar 

  19. Ruggiero, T. et al. A(H1N1)pdm09 hemagglutinin D222G and D222N variants are frequently harbored by patients requiring extracorporeal membrane oxygenation and advanced respiratory assistance for severe A(H1N1)pdm09 infection. Influenza Other Respir. Viruses 7, 1416–1426 (2013).

    Article  CAS  Google Scholar 

  20. Rykkvin, R., Kilander, A., Dudman, S.G. & Hungnes, O. Within-patient emergence of the influenza A(H1N1)pdm09 HA1 222G variant and clear association with severe disease, Norway. Euro Surveill. 18, 20369 (2013).

    PubMed  Google Scholar 

  21. Herfst, S. et al. Introduction of virulence markers in PB2 of pandemic swine-origin influenza virus does not result in enhanced virulence or transmission. J. Virol. 84, 3752–3758 (2010).

    Article  CAS  Google Scholar 

  22. Elderfield, R. A. et al. Accumulation of human-adapting mutations during circulation of A(H1N1)pdm09 influenza virus in humans in the United Kingdom. J. Virol. 88, 13269–13283 (2014).

    Article  Google Scholar 

  23. Chaussabel, D. et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29, 150–164 (2008).

    Article  CAS  Google Scholar 

  24. Pankla, R. et al. Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis. Genome Biol. 10, R127 (2009).

    Article  Google Scholar 

  25. Simon, L., Gauvin, F., Amre, D. K., Saint-Louis, P. & Lacroix, J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin. Infect. Dis. 39, 206–217 (2004).

    Article  CAS  Google Scholar 

  26. Wu, M. H. et al. Can procalcitonin tests aid in identifying bacterial infections associated with influenza pneumonia? A systematic review and meta-analysis. Influenza Other Respir. Viruses 7, 349–355 (2013).

    Article  CAS  Google Scholar 

  27. Falsey, A. R. et al. Bacterial complications of respiratory tract viral illness: a comprehensive evaluation. J. Infect. Dis. 208, 432–441 (2013).

    Article  CAS  Google Scholar 

  28. McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O’Garra, A. Type I interferons in infectious disease. Nat. Rev. Immunol. 15, 87–103 (2015).

    Article  CAS  Google Scholar 

  29. Marshall, J. C. Iatrogenesis, inflammation and organ injury: insights from a murine model. Crit. Care 10, 173 (2006).

    Article  Google Scholar 

  30. Openshaw, P. J. & Chiu, C. Protective and dysregulated T cell immunity in RSVinfection. Curr. Opin. Virol. 3, 468–474 (2013).

    Article  CAS  Google Scholar 

  31. Davidson, S., Crotta, S., McCabe, T. M. & Wack, A. Pathogenic potential of interferon alphabeta in acute influenza infection. Nat. Commun. 5, 3864 (2014).

    Article  CAS  Google Scholar 

  32. Gregory, D. J. & Kobzik, L. Influenza lung injury: mechanisms and therapeutic opportunities. Am. J. Physiol. Lung Cell. Mol. Physiol. 309, L1041–L1046 (2015).

    Article  CAS  Google Scholar 

  33. Short, K. R., Kroeze, E. J. B. V., Fouchier, R. A. M. & Kuiken, T. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect. Dis. 14, 57–69 (2014).

    Article  CAS  Google Scholar 

  34. Sandler, N. G. et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511, 601–605 (2014).

    Article  CAS  Google Scholar 

  35. Biron, C. A. Interferons alpha and beta as immune regulators-a new look. Immunity 14, 661–664 (2001).

    Article  CAS  Google Scholar 

  36. Narasaraju, T. et al. Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am. J. Pathol. 179, 199–210 (2011).

    Article  CAS  Google Scholar 

  37. Lukens, M. V. et al. A systemic neutrophil response precedes robust CD8+ T-cell activation during natural respiratory syncytial virus infection in infants. J. Virol. 84, 2374–2383 (2010).

    Article  CAS  Google Scholar 

  38. Tate, M. D., Brooks, A. G., Reading, P. C. & Mintern, J. D. Neutrophils sustain effective CD8+ T-cell responses in the respiratory tract following influenza infection. Immunol. Cell Biol. 90, 197–205 (2012).

    Article  CAS  Google Scholar 

  39. Lim, K. et al. Neutrophil trails guide influenza-specific CD8+ T cells in the airways. Science 349, aaa4352 (2015).

    Article  Google Scholar 

  40. Mayer-Barber, K. D. et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511, 99–103 (2014).

    Article  CAS  Google Scholar 

  41. Carr, M. J. et al. Development of a real-time RT-PCR for the detection of swine-lineage influenza A (H1N1) virus infections. J. Clin. Virol. 45, 196–199 (2009).

    Article  CAS  Google Scholar 

  42. Nguyen-Van-Tam, J. S. et al. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax 65, 645–651 (2010).

    Article  CAS  Google Scholar 

  43. Ashburner, M. et al. The Gene Ontology Consortium. Gene ontology: tool for the unification of biology. Nat. Genet. 25, 25–29 (2000).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

MOSAIC Study was supported by a joint award from the Wellcome Trust and the Medical Research Council (090382/Z/09/Z). We gratefully acknowledge the support of the MOSAIC administrative team (M. Cross, L.-A. Cumming, M. Minns, T. Ford, B. Cerutti, D. Gardner and Z. Williams) and the generosity of our patients and their families, healthy volunteers, and staff at participating National Health Service (NHS) hospitals (Alder Hey Children's Hospital; Brighton & Sussex University Hospitals NHS Trust; Central Manchester University Hospitals NHS Foundation Trust; Chelsea and Westminster Hospital NHS Foundation Trust; Imperial College Healthcare NHS Trust; Liverpool Women's NHS Foundation Trust; Royal Liverpool and Broadgreen University Hospitals NHS Trust; Royal Brompton and Harefield NHS Foundation Trust; University Hospitals Coventry and Warwickshire NHS Trust). In particular, we thank K. Alshafi, S. Ashton, E. Bailey, A. Bermingham, M. Berry, C. Bloom, A. Booth, E. Brannigan, S. Bremang, J. Clark, M. Cross, L. A. Cumming, S. Dyas, J. England-Smith, J. Enstone, D. Ferreira, N. Goddard, A. Godlee, S. Gormley, M. Guiver, M. O. Hassan-Ibrahim, H. Hill, P. Holloway, K. Hoschler, G. Houghton, F. Hughes, R. R. Israel, A. Jepson, K. D. Jones, W. P. Kelleher, M. Kidd, K. Knox, A. Lackenby, G. Lloyd, H. Longworth, S. Mookerjee, S. Mt-Isa, D. Muir, A. Paras, V. Pascual, L. Rae, S. Rodenhurst, F. Rozakeas, E. Scott, E. Sergi, N. Shah, V. Sutton, J. Vernazza, A.W. Walker, C. Wenden, T. Wotherspoon, A. D. Wright and F. Wurie. We also thank E. Anguiano and members of the Genomic Core, BIIR, Dallas, for assistance with the microarray analysis; and M. Berry for guidance. We especially thank the MOSAIC Data Team (L. Drumright, L. Garcia-Alvarez, J. Lieber, S. Mookerjee and B. Pamba) for assistance in collating and validating clinical data; R. Smyth for careful review of the manuscript; and K. Strimmer for statistical advice in revisions of the manuscript. F. Rozakeas helped with recruiting samples from all the healthy control subjects at NIMR (Mill Hill). The MOSAIC consortium (ClinicalTrials.gov identifier NCT00965354) was supported by UK National Institute for Health Research (NIHR) Comprehensive Local Research Networks (CLRNs), the Biomedical Research Centre (NIHR Imperial BRC) and Unit (NIHR Liverpool BRU), the Health Protection Research Unit in Respiratory Infections in partnership with Public Health England (PHE) at Imperial College London (NIHR HPRU RI), the Health Protection Agency (latterly PHE) Microbiology Services, Colindale and the staff of the Roslin Institute, Edinburgh, Scotland. A.O.G. and C.G. were supported by the Medical Research Council, United Kingdom (U117565642), The Francis Crick Institute, London (AOG10126, which receives its core funding from Cancer Research UK (FC001126)), the UK Medical Research Council (FC001126), the Wellcome Trust (FC001126) and the UK Medical Research Council (MR/U117565642/1). S.B. was in part jointly funded by the UK Medical Research Council (MRC) as above and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement (MR/J010723/1). C.B. was funded by an MRC CRTF. P.J.M.O. was supported by EU FP7 PREPARE project 602525. The views expressed are those of the authors and not necessarily those of the NHS, NIHR, Public Health England or the Department of Health (UK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

MOSAIC investigators:

Maximillian S. Habibi, Sebastian L. Johnston, Trevor T. Hansel, Mike Levin, Ryan S. Thwaites, John O. Warner, William O. Cookson, Brian G. Gazzard, Alan Hay, John McCauley, Paul Aylin, Deborah Ashby, Wendy S. Barclay, R. A. Elderfield, Simon Nadel, Jethro A. Herberg, Lydia N. Drumright, Laura Garcia-Alvarez, Alison H. Holmes, Onn M. Kon, Stephen J. Aston, Stephen B. Gordon, Tracy Hussell, Catherine Thompson, Maria C. Zambon, Kenneth J. Baillie, David A. Hume, Peter Simmonds, Andrew Hayward, Rosalind L. Smyth, Paul S. McNamara, Malcolm G. Semple, Jonathan S. Nguyen-Van-Tam, Ling-Pei Ho, Andrew J. McMichael, Paul Kellam, Walt E Adamson, William F Carman and Mark J. Griffiths

Author information

Authors and Affiliations

Authors

Consortia

Contributions

J.D., A.O.G. and P.J.M.O. conceived of and designed the study, with input from D.C. and J.B.; J.D., S.B., L.T.H. and C.I.B. analyzed the microarray data, with supervision by A.O.G. and P.J.M.O. and input from J.B. and D.C.; M.C., P.L.J. and M.F.M. performed and analyzed the microbiome experiments; C.M.G. performed the microarray experiments; J.D., S.J.B. and P.J.M.O. developed clinical protocols, recruited subjects and collated clinical data; and J.D., S.B., L.T.H., A.O.G. and P.J.M.O. wrote and revised the manuscript.

Corresponding authors

Correspondence to Anne O’Garra or Peter J. M. Openshaw.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Integrated supplementary information

Supplementary Figure 1 Interferon signaling pathway.

IPA canonical pathway for interferon signaling, identified as one of the top five canonical pathways for upregulated transcripts shown in Figure 1d (2010/11 cohort). Red shading represents up-regulated genes, blue represents down-regulated genes.

Supplementary Figure 2 Validation of transcriptional signatures in an independent cohort.

a) 2009/2010 cohort clustered on individuals and transcripts (Pearson’s uncentered with averaged linkage) using 1255 transcript list (from Figure 1). (b) 2009/2010 cohort clustered on individuals and transcripts (Pearson’s uncentered with averaged linkage) using 25 transcript list (from Figure 1). (c) 2009/2010 cohort clustered on individuals and transcripts (Pearson’s uncentered with averaged linkage) using 231 transcript list of severity (from Figure 2, transcripts retained if >2FC between severity 3 and severity 1&2). GO Terms analysis of 3 major branches of the transcripts dendrogram was undertaken and listed next to the heat-map. (d) Using 51 and 112 transcripts lists (from Figure 3) ‘viral response’ and ‘bacterial response’ molecular scores were calculated and plotted for each influenza patient (relative to healthy controls). Cases were coded according to severity of illness, indicated by the colour of the respective dots (severity 1, black; severity 2, blue; severity 3, red).

Supplementary Figure 3 Change of ‘viral’ and ‘bacterial’ molecular scores over time and association with influenza viral load.

(a) ‘Viral’ molecular scores plotted for 59 influenza patients (2010/11 cohort) who provided T1 and T2 samples, plotted against respective day of illness at time of sampling. (b) Change in ‘viral’ molecular score between first (T1) and precise second time point (48 hours after T1) in 41 patients with appropriate samples available (P= 0.0002, Mann-Whitney test, two-tailed). (c) ‘Bacterial’ molecular score plotted for 59 influenza patients who had both a T1 and a T2 sample, shown plotted against respective day of illness. (d) Change in ‘bacterial’ molecular score between T1 and precise T2 (48h post T1), in 41 patients with appropriate samples available (NS, Mann-Whitney test, two-tailed). (e) Influenza viral load estimation (pfu/ml) in nasopharyngeal samples obtained at T1 (n=42) and T2 (n=40). Bars show the median and interquartile range. Zero values were reassigned a value of 0.001 for display purposes. Mann Whitney test (two-tailed); ** P=0.0094. (f) Relationship between influenza viral load (pfu/ml) at T1 or T2 and the simultaneous ‘viral’ molecular score on whole blood (n=82).

Supplementary Figure 4 Administration of antibiotics does not affect ‘bacterial’ or ‘viral’ molecular scores.

(a) Influenza patients (2010/11 cohort) presenting within the first 14 days of illness grouped by administration of any antibiotic (n=35) or no administration of antibiotics (n=35) in the 24 hours prior to T1 sampling. There was no difference (NS, Mann-Whitney test, two tailed) in either bacterial or viral molecular scores between the two groups. Bars show the median and interquartile range. (b) Prescription of antibiotics after T1 did not significantly influence ‘bacterial’ molecular score (P=0.9616, Kruskal Wallis test). Fifty-nine influenza patients who had both T1 and T2 samples were grouped by those who did not receive antibiotics (n=7), those whose antibiotics were stopped at T1 (n=1), those who had antibiotics prescribed after T1 but before T2 (n=24), and those who were receiving antibiotics at both T1 and T2 (N=27). Bars show median with interquartile range. (c) Total 16S rRNA copies at T1 in throat swabs and NP aspirate in patients adjudicated to be with or without bacterial co-infection. Those with confirmed bacterial infections (Bac +) had greater levels of total 16S rRNA copies in NP aspirate than those deemed to be without co-infection (Bac -) (Mann- Whitney test, P = 0.036). Throat swab Bac -, n=44; throat swab bac +, n=53; NP aspirate Bac -, n=17; NP aspirate Bac +, n=41.

Supplementary Figure 5 Correlation of serum cytokines and bacterial load in nasophaynx with ‘viral’ and ‘bacterial’ molecular distance to health.

(a) Levels of IL-17 in the serum of healthy controls (HC, n=36) and influenza infected patients (severity 1-3; n=59, n=43, and n=31, respectively). (b) Concentration of IL-17 in broncoalveolar lavage (BAL) of HC (n=11) and from influenza patients’ BAL (n=8), NPA (n=8), nasadsoprtion fluid (SAM; n=8) and serum (n=8). (c) Correlation of levels of IL-17 in serum (n=165) with the bacterial MDTH (Spearman R =0.39, P<0.001). (d) Correlation of levels of TNF-α in serum (n=165) with bacterial MDTH (Spearman R = 0.4, P<0.01). (e) Total 16S rRNA gene copies in NP aspirate samples (n=58) are inversely correlated with the viral MDTH (Spearman R = -0.28, P value < 0.05). (f) Total 16S rRNA gene copies in NP aspirate samples (n=58) are positively correlated with the bacterial MDTH (Spearman R = 0.37, P value < 0.05).

Supplementary information

Supplementary Figures and Tables

Supplementary Figures 1-5; Supplementary Tables 1 and 2

Reporting Summary

Supplementary Dataset

Excel spreadsheet providing clinical data corresponding to raw and normalized microarray data deposited in GEO, Data Accession Code GSE111368.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dunning, J., Blankley, S., Hoang, L.T. et al. Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza. Nat Immunol 19, 625–635 (2018). https://doi.org/10.1038/s41590-018-0111-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-018-0111-5

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing